Published in Antiviral Res on February 01, 1989
Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ (2007) 1.22
Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med (2010) 1.18
Influenza antiviral resistance testing in new york and wisconsin, 2006 to 2008: methodology and surveillance data. J Clin Microbiol (2009) 1.10
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PLoS One (2015) 0.94
Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan. J Clin Microbiol (2001) 0.93
Adamantane-resistant influenza infection during the 2004-05 season. Emerg Infect Dis (2008) 0.84
Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro. PLoS One (2011) 0.84
Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract. Antimicrob Agents Chemother (1999) 0.82
A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling. CPT Pharmacometrics Syst Pharmacol (2014) 0.79
Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist (2017) 0.78
Use of antiviral prophylaxis in influenza outbreaks in long term care facilities. Can J Infect Dis (2000) 0.75
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Giant spin-orbit bowing in GaAs1-xBix. Phys Rev Lett (2006) 3.38
Failure of a single-headed kinesin to track parallel to microtubule protofilaments. Nature (1995) 3.16
Assessment of signs of influenza illness in the ferret model. J Virol Methods (1989) 3.07
Coupling of kinesin steps to ATP hydrolysis. Nature (1997) 3.02
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology (1997) 2.37
T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol (1998) 2.31
Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol (2005) 2.28
Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis (1989) 2.21
Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. Am J Med (1984) 2.05
Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology (1995) 1.86
Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics (1996) 1.77
Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis (1987) 1.68
Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis (1986) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Allergic reactions to workplace allergens. JAMA (1997) 1.57
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect (2006) 1.56
Evaluation of a possible association of urban air toxics and asthma. Environ Health Perspect (1995) 1.52
Encephalitis associated with erythema infectiosum. J Pediatr (1970) 1.51
Cell-mediated immunity in humans during viral infection. I. Effect of rubella on dermal hypersensitivity, phytohemagglutinin response, and T lymphocyte numbers. Infect Immun (1974) 1.50
Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus. J Virol (1988) 1.49
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy (1999) 1.45
Evaluation of occupational asthma from airborne egg protein exposure in multiple settings. Chest (1990) 1.45
House dust (1-3)-beta-D-glucan and wheezing in infants. Allergy (2007) 1.40
Transmission of rubella from newborns. A controlled study among young adult women and report of an unusual case. Am J Dis Child (1965) 1.39
Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology (1995) 1.36
C-Linker of cyclic nucleotide-gated channels controls coupling of ligand binding to channel gating. J Gen Physiol (1999) 1.35
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 1.35
Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis (1990) 1.32
The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis (1999) 1.32
Pulmonary and immunologic evaluation of foundry workers exposed to methylene diphenyldiisocyanate (MDI). J Allergy Clin Immunol (1988) 1.29
Effect of viral and bacterial pneumonias on cell-mediated immunity in humans. Infect Immun (1976) 1.29
Reye's syndrome: epidemiologic and viral studies, 1963-1974. Am J Epidemiol (1975) 1.28
A study of erythema infectiosum: recovery of rubella virus and echovirus-12. Pediatrics (1972) 1.27
Mediastinal and supraclavicular lymphadenitis and pneumonitis due to Chlamydia trachomatis serovars L1 and L2. N Engl J Med (1984) 1.25
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25
Acceptability of human papillomavirus self testing in female adolescents. Sex Transm Infect (2005) 1.24
Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis (2001) 1.23
Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis (1991) 1.23
Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis (1997) 1.22
A seroepidemiologic study of a measles epidemic in a highly immunized population. Am J Epidemiol (1972) 1.21
Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis (1993) 1.21
Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem (1998) 1.21
Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.20
Evidence for natural reassortants of human rotaviruses belonging to different genogroups. J Virol (1990) 1.20
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis (1998) 1.18
A combined respiratory and cutaneous hypersensitivity syndrome induced by work exposure to quaternary amines. J Allergy Clin Immunol (1994) 1.17
Association of Reye's syndrome with viral infection. Lancet (1974) 1.17
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine (2003) 1.15
Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc (1999) 1.14
Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis (2000) 1.14
Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother (1994) 1.14
The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections. J Infect Dis (1984) 1.13
Cellular immune response to cytomegalovirus infection after renal transplantation. Infect Immun (1978) 1.13
Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis (1995) 1.13
Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine (1998) 1.12
Complement is activated in the upper respiratory tract during influenza virus infection. Am Rev Respir Dis (1991) 1.11
Rubella-vaccinated students. Follow-up in a public school system. JAMA (1978) 1.10
Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.10
Measles IgM response during reinfection of previously vaccinated children. J Pediatr (1973) 1.10
The natural history of adult asthma: what do we know? Ann Allergy Asthma Immunol (2000) 1.10
Zosteriform spread of herpes simplex virus type 2 genital infection in the guinea-pig. J Gen Virol (1986) 1.09
Rubella vaccine evaluation in a public school system. Am J Dis Child (1969) 1.09
Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those unimmunized. J Pediatr (1982) 1.09
Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis (1994) 1.08
Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res (1988) 1.07
A pilot study concerning the infection risk of sputum positive tuberculosis patients on chemotherapy. Am Rev Respir Dis (1973) 1.06
Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. J Gen Virol (1986) 1.06
Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. Proc Natl Acad Sci U S A (1992) 1.05
Detection of IgE-mediated respiratory sensitization in workers exposed to hexahydrophthalic anhydride. J Allergy Clin Immunol (1985) 1.05
Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis (1978) 1.05
DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine (1996) 1.03
Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics (1982) 1.03
Local and systemic antibody response to rotavirus WC3 vaccine in adult volunteers. Antiviral Res (1989) 1.02
Measles antibody in previously immunized children. The need for revaccination. Am J Dis Child (1972) 1.02
Indirect assessment of 4,4'-diphenylmethane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin. Am J Ind Med (1998) 1.01
Immune responses in farm workers after exposure to Bacillus thuringiensis pesticides. Environ Health Perspect (1999) 1.01
Screening hospital patients for hepatitis B surface antigen. Am J Clin Pathol (1977) 1.01
DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis (1996) 1.00
Golgi-like, transneuronal retrograde labelling with CNS injections of herpes simplex virus type 1. Brain Res Bull (1989) 0.99
Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol (1993) 0.99
Rubella: recent laboratory and clinical advances. Prog Med Virol (1966) 0.98